Get to know our clinical trials
A clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and lenvatinib compared with a double-blind placebo and lenvatinib in participants with unresectable or metastatic hepatocellular carcinoma and ....
THE PURPOSE OF THIS TRIAL IS TO DETERMINE HOW WELL A NEW DRUG CURRENTLY IN DEVELOPMENT CALLED VISUGROMAB (ALSO KNOWN AS CTL-002) WORKS AND WHETHER IT IS SAFE WHEN USED IN COMBINATION WITH NIVOLUMAB AND LENVATINIB.
Technical Summary
- A RANDOMIZED, DOUBLE-BLIND PHASE 2B TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF VISUGROMAB IN COMBINATION WITH NIVOLUMAB AND LENVATINIB COMPARED WITH A DOUBLE PLACEBO AND LENVATINIB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA AND COMPENSATED LIVER FUNCTION (CHILD-PUGH CLASS A) FOLLOWING FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI-PD-(L)1 AGENT (GDFATHERHCC01).
- Code EudraCT: 2025-520675-86
- Protocol number: CTL-002-005
- Promoter: CatalYm GmbH
- Molecule/Drug: Visugromab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.